BC Gov News. (2022, May 31). BC receives exemption to decriminalize possession of some illegal drugs for personal use. Mental Health and Addictions. -

Hawk, M., Coulter, R. W. S., Egan, J. E., Fisk, S., Reuel Friedman, M., Tula, M., & Kinsky, S. (2017). Harm reduction principles for healthcare settings. Harm Reduction Journal, 14(1), 70.

Levengood, T. W., Yoon, G. H., Davoust, M. J., Ogden, S. N., Marshall, B. D. L., Cahill, S. R., & Bazzi, A. R. (2021). Supervised Injection Facilities as Harm Reduction: A Systematic Review. American Journal of Preventive Medicine, 61(5), 738–749.

Ng, J., Sutherland, C., & Kolber, M. R. (2017). Does evidence support supervised injection sites? Canadian Family Physician Medecin de Famille Canadien, 63(11), 866.Pergolizzi, J. v., Dahan, A., Ann LeQuang, J., & Raffa, R. B. (2021). Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. Journal of Clinical Pharmacy and Therapeutics, 46(6), 1501–1504.

Plunkett, A. R., & Peden, R. M. (2019). Opioid maintenance, weaning and detoxification techniques; where we have been, where we are now and what the future holds: an update. Pain Management, 9(3), 297–306.

Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 3(2), e1920622.

Xie, E., Green, S., Puri, N., & Sheikh, H. (2017). Updating our language around substance use disorders. Canadian Medical Association Journal, 189(50), E1566–E1566.

Centres for Disease Control and Prevention. (2018

CBC- 2021

Map for Naloxone Kit Dist

Additional Relevant Articles:
Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., Hart, C., Kerr, T., Lajous, A. M., Lewis, S., Martin, N., Mejía, D., Camacho, A., Mathieson, D., Obot, I., … Beyrer, C. (2016). Public health and international drug policy. The Lancet, 387(10026), 1427–1480.

Daniels, C., Aluso, A., Burke-Shyne, N., Koram, K., Rajagopalan, S., Robinson, I., Shelly, S., Shirley-Beavan, S., & Tandon, T. (2021). Decolonizing drug policy. Harm Reduction Journal, 18(1), 120.

Dea, S. (2020). Toward a Philosophy of Harm Reduction. Health Care Analysis, 28(4), 302–313.

Huhn, A. S., & Gipson, C. D. (2021). Promoting harm reduction as a treatment outcome in substance use disorders. Experimental and Clinical Psychopharmacology, 29(3), 217–218.

Pauly, B. (2008). Harm reduction through a social justice lens. International Journal of Drug Policy, 19(1), 4–10.

Shearer, D., Fleming, T., Fowler, A., Boyd, J., & McNeil, R. (2019). Naloxone distribution, trauma, and supporting community-based overdose responders. International Journal of Drug Policy, 74, 255–256.

Vicknasingam, B., Narayanan, S., Singh, D., & Chawarski, M. (2018). Decriminalization of drug use. Current Opinion in Psychiatry, 31(4), 300–305.